AlphaCrest Capital Management’s Haemonetics HAE Stock Holding History

AlphaCrest Capital Management’s Portfolio HAE Stock Details HAE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-8,883	Closed	-$658K	–	494
2022 Q3	$658K	Buy	+8,883	New	+$638K	0.04%	849
2022 Q2	–	Sell	-3,209	Closed	-$203K	–	1295
2022 Q1	$203K	Sell	3,209 -8,957	-74%	-$487K	0.01%	1207
2021 Q4	$645K	Buy	+12,166	New	+$741K	0.02%	999
2021 Q3	–	Sell	-3,410	Closed	-$227K	–	1295
2021 Q2	$227K	Sell	3,410 -2,123	-38%	-$150K	0.01%	1176
2021 Q1	$614K	Buy	5,533 +1,377	+33%	+$170K	0.03%	708
2020 Q4	$494K	Buy	+4,156	New	+$447K	0.04%	658
2020 Q3	–	Sell	-3,339	Closed	-$299K	–	1136
2020 Q2	$299K	Buy	3,339 +604	+22%	+$61K	0.05%	630
2020 Q1	$273K	Sell	2,735 -854	-24%	-$92.6K	0.03%	830
2019 Q4	$412K	Buy	3,589 +484	+16%	+$58.6K	0.03%	904
2019 Q3	$392K	Buy	+3,105	New	+$394K	0.02%	1024
2019 Q2	–	Sell	-5,182	Closed	-$453K	–	1071
2019 Q1	$453K	Buy	+5,182	New	+$471K	0.07%	500

Other funds holding HAE

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return

AlphaCrest Capital Management's HAE Position: Q4 2022 in Review

AlphaCrest Capital Management sold out of Haemonetics (HAE) in Q4 2022, closing a stake of 8,883 shares — an estimated $658K sold.

AlphaCrest Capital Management first reported a position in HAE in Q1 2019 and held it in 11 quarters. The position peaked at $658K in Q3 2022. 294 funds tracked by Wall St. Rank hold HAE as of Q4 2022.

AlphaCrest Capital Management reported no remaining Haemonetics position as of Q4 2022 after selling out during the quarter.
AlphaCrest Capital Management sold 8,883 Haemonetics shares in Q4 2022, an estimated $658K.
AlphaCrest Capital Management first reported a position in Haemonetics in Q1 2019 and held it in 11 quarters.
AlphaCrest Capital Management's Haemonetics position peaked at $658K in Q3 2022.
294 funds tracked by Wall St. Rank held Haemonetics as of Q4 2022.

Based on AlphaCrest Capital Management's 13F filing for Q4 2022.